2-year Caries Clinical Study: Arginine Fluoride-Free Toothpastes vs. NaF Toothpaste

Sponsor
Colgate Palmolive (Industry)
Overall Status
Completed
CT.gov ID
NCT05560945
Collaborator
(none)
6,000
3
3
34.9
2000
57.3

Study Details

Study Description

Brief Summary

The objective of this study is to evaluate the anticaries efficacy for three dentifrices (1.5% arginine in a calcium base, 8.0% arginine in a calcium base, and 0.32% sodium fluoride in a silica base) in a two-year caries clinical study

Condition or Disease Intervention/Treatment Phase
  • Drug: 0.32% Sodium Fluoride Dentifrice Toothpaste
  • Drug: 1.5% Arginine Dentifrice
  • Drug: 8.0% Arginine Dentifrice
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
6000 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Clinical Investigation Examining the Anticaries Efficacy of Three Dentifrices (1.5% Arginine in a Calcium Base, 8.0% Arginine in a Calcium Base, and 0.32% Sodium Fluoride in a Silica Base): a Two-year Caries Clinical Study
Actual Study Start Date :
Apr 15, 2019
Actual Primary Completion Date :
Mar 12, 2022
Actual Study Completion Date :
Mar 12, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: 0.32% Sodium Fluoride Dentifrice Toothpaste

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Drug: 0.32% Sodium Fluoride Dentifrice Toothpaste
Toothpaste

Experimental: 1.5% Arginine Dentifrice Toothpaste

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Drug: 1.5% Arginine Dentifrice
Toothpaste

Experimental: 8.0% Arginine Dentifrice Toothpaste

Whole mouth brushing with a toothpaste, 2 times/day for 2 minutes each time for the duration of the study

Drug: 8.0% Arginine Dentifrice
Toothpaste

Outcome Measures

Primary Outcome Measures

  1. The primary efficacy endpoint will be the incremental subject-wise Decayed Missing Filled Surfaces score after 2 year product use. [2 year]

    the minimum score is 0, maximum score is 4/5 depending on the tooth number and a higher score represents a worse outcome

  2. The primary efficacy endpoint will be the incremental subject-wise Decayed Missing Filled Teeth scores after two year of product use. [2 year]

    the minimum score is 0, maximum score is 4/5 depending on the tooth number and a higher score represents a worse outcome

Eligibility Criteria

Criteria

Ages Eligible for Study:
10 Years to 14 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Informed Consent Form signed by parent or legal guardian to permit participation of their child in the study

  • Willingness and ability to use the assigned products according to instructions, availability for all appointments and likelihood of completing the clinical trial.

  • Children ages 10-14 years at baseline.

  • Presence of second molars or evidence of erupting permanent molars.

  • Subjects should be of good general health as evidenced by a review of the medical history.

  • Presence of two or more active caries lesions (ICDAS scores of 2 or greater) and with a previous caries experience (DMFS ≥ 2). Exclusion Characteristics

  • Subjects presenting with any of the criteria below will be excluded from the study:

  • Presence of fixed or removable prosthetic appliance or orthodontic treatment involving more than four permanent teeth.

  • Use of medication that could increase the risk of developing dental caries, i.e. medication that reduces saliva flow.

  • Long-term antibiotic therapy.

  • Children with cognitive and/or motor impairment.

  • Severe malocclusion.

  • Presence of severe caries (ICDAS 5 or 6) on five or more teeth.

  • Evidence of moderate to severe periodontal disease.

  • Participation in any other clinical study within the 30 days preceding the clinical study.

  • History of allergies or other adverse reactions to arginine, or oral care products, or their ingredients.

  • Pregnant or lactating.

Contacts and Locations

Locations

Site City State Country Postal Code
1 School of Stomatology, Xian Jiaotong University Xi'an Shaanxi China 710004
2 West China School of Stomatology, Sichuan University Chengdu Sichuan China 610041
3 School of Stomatology Chongqing Medical University Chongqing China 400016

Sponsors and Collaborators

  • Colgate Palmolive

Investigators

  • Study Director: Yun Po E Zhang, PhD, DDS(Hons), Colgate Palmolive

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Colgate Palmolive
ClinicalTrials.gov Identifier:
NCT05560945
Other Study ID Numbers:
  • CRO-2018-12-CAR-ARG-YPZ
First Posted:
Sep 30, 2022
Last Update Posted:
Oct 3, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Colgate Palmolive
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 3, 2022